Literature DB >> 17522224

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.

Michael A Lobritz1, Andre J Marozsan, Ryan M Troyer, Eric J Arts.   

Abstract

Natural polymorphisms in the heterogeneous human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein may have an impact on both sensitivity to entry inhibitors and viral replicative fitness. Of significant interest is variation in the V3 crown due to its involvement in direct engagement with the coreceptor. Two positions in the crown (318 and 319) appear to be important in determining intrinsic susceptibility to multiple entry inhibitors. Thus, we evaluated a series of natural polymorphisms at positions 318 and 319 in three distinct CCR5-tropic envelope genetic backgrounds to address their role in replicative fitness and sensitivity to entry inhibitors. Change at position 319 to each of the three major consensus amino acids (A, T, and R) resulted in variation in sensitivity to entry inhibitors and altered replicative fitness, but the effects of any one amino acid depended on the envelope context. Change of the nearly invariant tyrosine at position 318 to a rare arginine resulted in increased sensitivity to entry inhibitors and decreased replicative fitness independent of envelope context. Polymorphisms in the V3 crown that showed increased susceptibility to entry inhibitors also exhibited decreased entry efficiency, replicative fitness in primary peripheral blood mononuclear cells, and ability to replicate in primary macrophages. These findings suggest that differences in coreceptor affinity and/or avidity may underlie these phenotypic characteristics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522224      PMCID: PMC1951322          DOI: 10.1128/JVI.02739-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.

Authors:  B Lee; M Sharron; C Blanpain; B J Doranz; J Vakili; P Setoh; E Berg; G Liu; H R Guy; S R Durell; M Parmentier; C N Chang; K Price; M Tsang; R W Doms
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

2.  Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors.

Authors:  Fronsje A Koning; Cindy Koevoets; Teun J K van der Vorst; Hanneke Schuitemaker
Journal:  Antivir Ther       Date:  2005

3.  The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.

Authors:  Kevin K Ariën; Awet Abraha; Miguel E Quiñones-Mateu; Luc Kestens; Guido Vanham; Eric J Arts
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

Authors:  E A Berger; P M Murphy; J M Farber
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

5.  Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Authors:  Peter Rusert; Herbert Kuster; Beda Joos; Benjamin Misselwitz; Cornelia Gujer; Christine Leemann; Marek Fischer; Gabriela Stiegler; Hermann Katinger; William C Olson; Rainer Weber; Leonardo Aceto; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.

Authors:  Emily J Platt; James P Durnin; David Kabat
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

Authors:  D E Mosier; G R Picchio; R J Gulizia; R Sabbe; P Poignard; L Picard; R E Offord; D A Thompson; J Wilken
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

Authors:  Andre J Marozsan; Shawn E Kuhmann; Thomas Morgan; Carolina Herrera; Enid Rivera-Troche; Serena Xu; Bahige M Baroudy; Julie Strizki; John P Moore
Journal:  Virology       Date:  2005-07-20       Impact factor: 3.616

9.  Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.

Authors:  Andre J Marozsan; Dawn M Moore; Michael A Lobritz; Erika Fraundorf; Awet Abraha; Jacqueline D Reeves; Eric J Arts
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

10.  Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion.

Authors:  Samvel R Mkrtchyan; Ruben M Markosyan; Michael T Eadon; John P Moore; Gregory B Melikyan; Fredric S Cohen
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more
  33 in total

1.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

2.  Conserved determinants of enhanced CCR5 binding in the human immunodeficiency virus subtype D envelope third variable loop.

Authors:  Samaporn Teeravechyan; M Essex; Tun-Hou Lee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

3.  HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Authors:  Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-16       Impact factor: 2.205

4.  Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.

Authors:  Wuwei Wu; Derek C Blythe; Hyelee Loyd; Robert H Mealey; Rebecca L Tallmadge; Karin S Dorman; Susan Carpenter
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 5.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

6.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

7.  HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Authors:  Annette N Ratcliff; Wuxian Shi; Eric J Arts
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

8.  Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation.

Authors:  Aemro Kassa; Andrés Finzi; Marie Pancera; Joel R Courter; Amos B Smith; Joseph Sodroski
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

Authors:  Behzad Etemad; Angela Fellows; Brenda Kwambana; Anupa Kamat; Yang Feng; Sandra Lee; Manish Sagar
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

10.  Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics.

Authors:  Kara G Lassen; Michael A Lobritz; Justin R Bailey; Samantha Johnston; Sandra Nguyen; Benhur Lee; Tom Chou; Robert F Siliciano; Martin Markowitz; Eric J Arts
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.